Sobuzoxane (CAS 98631-95-9)
See product citations (1)
QUICK LINKS
Sobuzoxane is a compound of interest mainly in the field of chemistry and biochemistry for its role as an intercalating agent. Research on Sobuzoxane focuses on its interaction with DNA, where it intercalates between base pairs, affecting the structure and stability of the DNA helix. This intercalation process is significant in understanding the mechanisms of DNA binding by small molecules and their potential to alter DNA function. Studies utilizing Sobuzoxane also delve into the kinetics and thermodynamics of its binding to nucleic acids, providing insights into the molecular aspects of ligand-DNA interactions. In addition to its DNA-binding properties, Sobuzoxane is used in investigations pertaining to DNA repair pathways, as compounds that intercalate into DNA can induce a biological response to DNA damage. The compound′s ability to disrupt normal DNA processes is therefore a useful tool in elucidating the complex series of events that maintain genomic integrity.
Sobuzoxane (CAS 98631-95-9) References
- MST-16, a novel bis-dioxopiperazine anticancer agent, ameliorates doxorubicin-induced acute toxicity while maintaining antitumor efficacy. | Yoshida, M., et al. 1999. Clin Cancer Res. 5: 4295-300. PMID: 10632373
- Long-term administration of oral low-dose topoisomerase II inhibitors, MST-16 and VP-16, for refractory or relapsed non-Hodgkin's lymphoma. | Okamoto, T., et al. 2000. Acta Haematol. 104: 128-30. PMID: 11154989
- The cardio-protecting agent and topoisomerase II catalytic inhibitor sobuzoxane enhances doxorubicin-DNA adduct mediated cytotoxicity. | Swift, LP., et al. 2008. Cancer Chemother Pharmacol. 61: 739-49. PMID: 17594094
- Case of adult T-cell leukemia with pulmonary involvement presenting as nodular shadows. | Oyama, K., et al. 2008. J Dermatol. 35: 225-8. PMID: 18419680
- BCR/ABL downregulates DNA-PK(CS)-dependent and upregulates backup non-homologous end joining in leukemic cells. | Poplawski, T. and Blasiak, J. 2010. Mol Biol Rep. 37: 2309-15. PMID: 19697154
- Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells. | Vavrova, A., et al. 2013. PLoS One. 8: e76676. PMID: 24116135
- Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma. | Ishitsuka, K. and Tamura, K. 2014. Lancet Oncol. 15: e517-26. PMID: 25281470
- UHPLC-MS/MS method for analysis of sobuzoxane, its active form ICRF-154 and metabolite EDTA-diamide and its application to bioactivation study. | Reimerová, P., et al. 2019. Sci Rep. 9: 4524. PMID: 30872754
- MTX-HOPE is a low-dose salvage chemotherapy for aged patients with relapsed or refractory non-Hodgkin lymphoma. | Suzuki, M., et al. 2021. J Clin Exp Hematop. 61: 22-28. PMID: 33551437
- Clinical feasibility of oral low-dose etoposide and sobuzoxane for conventional chemotherapy-intolerant lymphoma patients. | Ohmoto, A. and Fuji, S. 2021. Expert Rev Anticancer Ther. 21: 715-722. PMID: 33656972
- bis(2,6-dioxopiperaxine) derivatives, topoisomerase II inhibitors which do not form a DNA cleavable complex, induce thymocyte apoptosis. | Onishi, Y., et al. 1994. Biochem Mol Biol Int. 32: 115-22. PMID: 8012276
- Testicular degeneration induced in rat offspring by maternal treatment with sobuzoxane. | Kato, I., et al. 1996. Reprod Toxicol. 10: 209-14. PMID: 8738557
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Sobuzoxane, 5 mg | sc-215862 | 5 mg | $255.00 | |||
Sobuzoxane, 25 mg | sc-215862A | 25 mg | $918.00 | |||
Sobuzoxane, 50 mg | sc-215862B | 50 mg | $1530.00 | |||
Sobuzoxane, 100 mg | sc-215862C | 100 mg | $2856.00 |